Indivior PLC (NASDAQ:INDV) Receives Consensus Rating of “Moderate Buy” from Analysts

Posted by on Aug 26th, 2026

Indivior PLC (NASDAQ:INDV – Get Free Report) has received an average rating of “Moderate Buy” from the seven research firms that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $45.1667.

Several equities analysts have recently commented on INDV shares. Weiss Ratings lowered Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday. Zacks Research lowered shares of Indivior from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 29th. Craig Hallum reiterated a “buy” rating and set a $53.00 target price on shares of Indivior in a report on Tuesday, August 4th. Finally, Barclays cut their target price on shares of Indivior from $46.00 to $43.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 5th.

View Our Latest Stock Analysis on INDV

Insider Activity

In related news, CAO Woodrow D. Anderson bought 1,500 shares of the stock in a transaction on Wednesday, August 5th. The stock was bought at an average price of $36.28 per share, for a total transaction of $54,420.00. Following the completion of the acquisition, the chief accounting officer directly owned 26,138 shares in the company, valued at approximately $948,286.64. This represents a 6.09% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Christian Heidbreder sold 18,586 shares of the stock in a transaction on Friday, July 10th. The shares were sold at an average price of $41.14, for a total value of $764,628.04. Following the sale, the insider directly owned 209,337 shares in the company, valued at $8,612,124.18. This trade represents a 8.15% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.74% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. California State Teachers Retirement System purchased a new stake in shares of Indivior during the 2nd quarter worth $201,163,000. Fuller & Thaler Asset Management Inc. raised its holdings in Indivior by 101.0% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 6,371,534 shares of the company’s stock worth $228,611,000 after purchasing an additional 3,201,639 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Indivior during the fourth quarter valued at about $82,687,000. Vanguard Group Inc. lifted its position in shares of Indivior by 57.9% during the fourth quarter. Vanguard Group Inc. now owns 5,473,891 shares of the company’s stock valued at $196,403,000 after buying an additional 2,008,078 shares during the last quarter. Finally, State Street Corp boosted its holdings in shares of Indivior by 65.5% in the 4th quarter. State Street Corp now owns 4,659,281 shares of the company’s stock valued at $167,175,000 after buying an additional 1,844,532 shares in the last quarter. 60.33% of the stock is owned by institutional investors.

Indivior Stock Down 0.6%

Shares of NASDAQ:INDV opened at $35.97 on Wednesday. The business’s 50 day moving average is $39.50 and its 200 day moving average is $35.99. The stock has a market cap of $4.24 billion, a P/E ratio of 12.89 and a beta of 0.86. Indivior has a 52-week low of $22.22 and a 52-week high of $42.81.

Indivior (NASDAQ:INDV – Get Free Report) last issued its earnings results on Tuesday, June 30th. The company reported $5.75 earnings per share for the quarter. Indivior had a negative return on equity of 283.11% and a net margin of 26.65%.The business had revenue of $343.00 million during the quarter. On average, sell-side analysts anticipate that Indivior will post 3.66 EPS for the current fiscal year.

Indivior Company Profile

(Get Free Report)

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.

Featured Articles

Analyst Recommendations for Indivior (NASDAQ:INDV)

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.